Turing Pharmaceuticals AG Announces IND Filing for TUR-004

ZUG, Switzerland, Oct. 5, 2015 /PRNewswire/ -- Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today announced that an Investigational New Drug Application (IND) for TUR-004 was submitted to the United States Food and Drug Administration on Tuesday, September 22, 2015.

TUR-004 is intended for use as an adjunctive therapy for refractory generalized seizures in patients with epileptic encephalopathies. The first study in the clinical program will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of an oral formulation of TUR-004 in healthy adult subjects.

"We are excited about the potential use of TUR-004 for helping people with this severe form of epilepsy," said Eliseo Salinas, M.D., MSc, President of Research and Development. He added, "We feel very strongly that clinical studies of TUR-004 will lead to the availability of TUR-004 and help to improve patients' lives."

Individuals with epileptic encephalopathies face a higher incidence of sudden unexplained death, status epilepticus and severely diminished quality of life.  Epileptic encephalopathies are a diverse group of severe epilepsy disorders in which uncontrolled epileptic activity contributes to a progressive decline in cognitive and motor function.

Martin Shkreli, founder and CEO of Turing Pharmaceuticals said, "TUR-004 is the first of multiple investigational new drug applications we expect to file in the next twelve months as a result of our focused research and development programs."

About Turing

Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in Zug Switzerland and New York, New York.  Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Products being developed include intranasal ketamine for a variety of mood disorders and Syntocinon(r) (oxytocin nasal solution) for multiple indications. Daraprim (pyrimethamine) for the treatment of Toxoplasmosis in combination with sulfonamide and Vecamyl(r) (mecamylamine HCl tablets) for hypertension are Turing's first commercial products.

For more, visit www.turingpharma.com.  

Media contact:  Allan Ripp 212-262-7477 [email protected]
Investor Relations:  Edward Painter 646-356-5577[email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.